Opinion|Videos|January 26, 2026
Other Key AML Data to Emerge From ASH 2025
Courtney D. DiNardo, MD, MSCE, and Jessica K. Altman, MD, highlight other key AML data from the 2025 ASH Annual Meeting.
Advertisement
Episodes in this series
Courtney D. DiNardo, MD, MSCE, and Jessica K. Altman, MD, highlight additional acute myeloid leukemia (AML) studies presented at the 2025 ASH Annual Meeting and Exposition with potential implications for clinical practice. They discuss emerging data across molecular subsets, novel agents, and evolving combination strategies. DiNardo and Altman conclude the program with an outro reflecting on how these findings may shape the future of AML treatment.
Advertisement
Related to this article
Petosemtamab plus pembrolizumab cut the risk of death by 50% in first-line PD-L1–positive recurrent or metastatic head and neck squamous cell carcinoma.
Relacorilant plus nab-paclitaxel and bevacizumab produced a 59% response rate in platinum-resistant ovarian cancer in Part A of the BELLA trial.
Updated ASTRO recommendations favor moderate hypofractionation for all risk groups and establish 5-fraction ultrahypofractionation as a standard option in localized prostate cancer.
Updated GOBLET cohort 4 data showed a median DOR of about 15 months with pelareorep plus atezolizumab in second-line or later anal cancer.
Firmonertinib demonstrated durable antitumor activity in patients with EGFR PACC-mutated NSCLC in a phase 1b trial.
The IMpactMF trial is being discontinued after an IDMC advised that imetelstat was unlikely to improve OS in relapsed/refractory myelofibrosis.
Sac-TMT plus pembrolizumab prolonged PFS over chemoimmunotherapy in PD-L1–negative nonsquamous lung cancer.
The FDA received a BLA for etentamig in relapsed/refractory multiple myeloma, based on response and PFS gains in the phase 3 CERVINO trial.
Advertisement
Advertisement
Trending on OncLive
1
FDA Receives BLA for Etentamig in R/R Multiple Myeloma
2
Breaking Down Key Lung Cancer Data at ESMO 2026 With Drs Santos and Halmos
3
Petosemtamab Plus Pembrolizumab Hits Phase 3 OS, ORR Primary End Points in PD-L1+ R/M HNSCC
4
Sac-TMT Plus Pembrolizumab Improves PFS in PD-L1–Negative Nonsquamous NSCLC
5